NeuroPace
Venture Round in 2013
NeuroPace, Inc. is a commercial-stage medical device company based in Mountain View, California, that specializes in the treatment of neurological disorders through innovative implantable devices. Founded in 1997, NeuroPace has developed the Responsive Neurostimulator (RNS) System, which is designed to monitor and respond to brain activity in patients with medically refractory partial epilepsy. The RNS System includes a small implantable neurostimulator connected to leads placed in seizure onset areas, delivering targeted electrical pulses to help reduce or eliminate seizures. NeuroPace primarily generates revenue from the sales of its RNS System to hospitals and specialized medical facilities that perform the implantation procedures.
OptiScan Biomedical
Private Equity Round in 2013
OptiScan Biomedical Corporation, founded in 1994 and located in Hayward, California, specializes in developing bedside blood monitoring systems for critically ill patients in intensive care units (ICUs). The company's flagship product, the OptiScanner 5000, is an automated glucose monitoring platform that utilizes spectroscopy technology to measure plasma glucose levels directly, eliminating the need for calibration. This system enables healthcare providers to rapidly detect changes in glucose levels, thus supporting better management of critically ill patients' health.
Pulmonx
Private Equity Round in 2012
Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.
NeuroPace
Venture Round in 2011
NeuroPace, Inc. is a commercial-stage medical device company based in Mountain View, California, that specializes in the treatment of neurological disorders through innovative implantable devices. Founded in 1997, NeuroPace has developed the Responsive Neurostimulator (RNS) System, which is designed to monitor and respond to brain activity in patients with medically refractory partial epilepsy. The RNS System includes a small implantable neurostimulator connected to leads placed in seizure onset areas, delivering targeted electrical pulses to help reduce or eliminate seizures. NeuroPace primarily generates revenue from the sales of its RNS System to hospitals and specialized medical facilities that perform the implantation procedures.
Spinal Modulation
Series D in 2011
Spinal Modulation, Inc., headquartered in Menlo Park, California, specializes in the development of advanced medical devices aimed at treating chronic pain. The company's flagship product, the Axium Neurostimulator System, represents a novel approach to pain management through intraspinal neuromodulation. This system specifically stimulates the dorsal root ganglion (DRG), providing an innovative alternative for patients suffering from chronic intractable leg pain and other challenging pain conditions such as those affecting the back and foot. By effectively targeting the DRG, the Axium system offers the ability to deliver adjustable therapies that can be tailored to address both broad and localized pain areas, while minimizing discomfort associated with traditional spinal cord stimulators. This technology addresses a significant unmet need in pain management, aiming to alleviate the burden on patients and healthcare systems alike.
PolyRemedy
Series C in 2011
PolyRemedy offers integrated wound management systems designed to increase consistency by extending wound care expertise to the point of care. The PolyRemedy Personalized Woundcare System (PWS) enables clinicians to document care through easy-to-use, web-based assessment tools and order personalized wound dressings, while also providing critical and unprecedented visibility into wound care data. It was founded in 2004 and is headquartered in Concord, Massachusetts.
Activaero
Series A in 2011
Activaero GmbH is a drug delivery company specializing in controlled breathing technologies designed for the pulmonary delivery of inhaled therapeutic agents. Founded in 2004 and based in Gemunden, Germany, with additional locations in Munich and Dublin, Ohio, Activaero develops innovative devices such as AKITA, which utilizes smart card technology for efficient drug delivery, and Watchhaler, specifically designed for children requiring inhaled medication. The company also offers AKITA², a technology for use in clinical trials, and LimiX, a flow limitation valve that regulates inhalation flow rates. In addition to its product offerings, Activaero provides measurement and diagnostic technologies for laboratory applications, including aerosol property measurement systems. Furthermore, the company engages in contract development and clinical trial logistics services, marketing its products through a network of distributors. Activaero's solutions aim to improve therapy outcomes for patients suffering from severe respiratory diseases, including asthma, chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis.
Sonoma Orthopedic Products
Series D in 2011
Sonoma Orthopedic Products is an orthopedic device company focused on designing, developing, and delivering proprietary orthopedic implants to address complex fractures. Utilizing the WaviBody technology platform, the company provides innovative surgical solutions that are minimally invasive, catering specifically to active patients. The firm specializes in fracture fixation devices that facilitate the repair of challenging bone geometries, enabling orthopedic surgeons to effectively restore function and return patients to their daily activities more rapidly. By prioritizing ease of use and efficacy in their products, Sonoma Orthopedic Products aims to enhance the recovery process for individuals with problematic fractures.
Game Ready
Debt Financing in 2010
Game Ready is a medical device company specializing in post-surgical orthopedic and sports injury treatment. Its primary product, GameReady, combines active pneumatic compression and adjustable cold therapies to facilitate faster recovery for athletes and patients post-injury or surgery.
Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.
eNeura Therapeutics
Venture Round in 2010
eNeura Inc. is a medical technology company focused on developing portable, non-invasive transcranial magnetic stimulation (TMS) devices for the treatment and prevention of migraines. Its flagship product, the sTMS mini, utilizes single-pulse TMS to provide migraine relief by generating targeted magnetic fields that pass through bone and tissue. This device is designed for both acute and prophylactic treatment of migraines in adolescents aged 12 and older, as well as adults, allowing for convenient use at home or on the go. eNeura was established in 2012 and is headquartered in San Jose, California, with an additional office in Baltimore, Maryland. The company, formerly known as eNeura Therapeutics LLC, rebranded in February 2014. However, it faced financial difficulties and filed for liquidation under Chapter 7 in August 2020.
Spinal Modulation
Series C in 2009
Spinal Modulation, Inc., headquartered in Menlo Park, California, specializes in the development of advanced medical devices aimed at treating chronic pain. The company's flagship product, the Axium Neurostimulator System, represents a novel approach to pain management through intraspinal neuromodulation. This system specifically stimulates the dorsal root ganglion (DRG), providing an innovative alternative for patients suffering from chronic intractable leg pain and other challenging pain conditions such as those affecting the back and foot. By effectively targeting the DRG, the Axium system offers the ability to deliver adjustable therapies that can be tailored to address both broad and localized pain areas, while minimizing discomfort associated with traditional spinal cord stimulators. This technology addresses a significant unmet need in pain management, aiming to alleviate the burden on patients and healthcare systems alike.
Sleep Solutions
Series F in 2009
Sleep Solutions (SSI) is a privately held diagnostic service provider specializing in the evaluation and home testing of sleep-disordered breathing, particularly Obstructive Sleep Apnea (OSA). The company offers an efficient and cost-effective alternative to traditional in-laboratory sleep studies, utilizing its proprietary sound analysis technology. Through its NovaSom QSG home-diagnostic system, Sleep Solutions delivers testing directly to patients, facilitating a more comfortable experience. In addition to diagnosis, the company provides services focused on therapy and compliance management for individuals affected by sleep-disordered breathing.
BeneChill
Series C in 2009
BeneChill, Inc. is a medical device company based in San Diego, California, specializing in the development of non-invasive cooling technologies aimed at enhancing patient outcomes following acute ischemic events, including cardiac arrest, stroke, and traumatic brain injury. Founded in 2004, BeneChill's flagship product, the RhinoChill System, is designed to effectively reduce patient temperature, which is critical in improving survival rates and recovery in critical care settings. The company's innovative approach addresses a significant need in the healthcare sector by providing advanced solutions that support patient care during life-threatening situations.
SpinalMotion
Series C in 2009
SpinalMotion is a private company focused on preserving spinal motion for patients suffering from degenerative disc disease. Founded in 2004, the company specializes in the development of innovative artificial disc implants that utilize proprietary Kineflex Technology, designed to maintain the natural movement of the spine while offering low wear and improved longevity. Since obtaining FDA approval in 2005 to conduct clinical trials for lumbar and cervical artificial discs in the United States, SpinalMotion has built on its international clinical experience to enhance patient outcomes. The company has attracted investment from notable partners, including Southern Medical, Three Arch Partners, Skyline Ventures, and MedVenture Associates, to further its mission of enabling patients to lead pain-free and healthy lives.
NanoVasc is a pioneering medical device company specializing in the design and manufacture of biomimetic materials. These materials are engineered to be non-thrombogenic, durable, and capable of maintaining long-term patency. Utilizing an electrospinning process, NanoVasc produces scaffolds in various shapes and sizes, which are then customized with application-specific modifications on the scaffold's surface. These modifications are meticulously crafted to optimize device performance based on its intended deployment location. The company's flagship product is a synthetic vascular graft specifically developed for hemodialysis access. This innovative graft aims to improve patient outcomes by providing a reliable and effective alternative to traditional vascular access methods. NanoVasc's dedication to biomimetic design and precision engineering underscores its commitment to advancing medical solutions that enhance the quality of patient care in vascular health.
PolyRemedy
Series B in 2008
PolyRemedy offers integrated wound management systems designed to increase consistency by extending wound care expertise to the point of care. The PolyRemedy Personalized Woundcare System (PWS) enables clinicians to document care through easy-to-use, web-based assessment tools and order personalized wound dressings, while also providing critical and unprecedented visibility into wound care data. It was founded in 2004 and is headquartered in Concord, Massachusetts.
Amnis Corporation
Series C in 2008
Amnis manufactures and supplies flow cytometry products and services. Their technology is used in research and clinical studies with biomedical and therapeutic applications, including investigating the role of the body’s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients.
Pavad Medical
Series C in 2007
PAVAD Medical, Inc., a medical device startup company, develops therapeutic technologies in the areas of obstructive sleep apnea. The company was incorporated in 2002 and is based in Fremont, California.
Game Ready
Venture Round in 2007
Game Ready is a medical device company specializing in post-surgical orthopedic and sports injury treatment. Its primary product, GameReady, combines active pneumatic compression and adjustable cold therapies to facilitate faster recovery for athletes and patients post-injury or surgery.
BeneChill
Series B in 2007
BeneChill, Inc. is a medical device company based in San Diego, California, specializing in the development of non-invasive cooling technologies aimed at enhancing patient outcomes following acute ischemic events, including cardiac arrest, stroke, and traumatic brain injury. Founded in 2004, BeneChill's flagship product, the RhinoChill System, is designed to effectively reduce patient temperature, which is critical in improving survival rates and recovery in critical care settings. The company's innovative approach addresses a significant need in the healthcare sector by providing advanced solutions that support patient care during life-threatening situations.
Intact Medical
Series G in 2007
Intact Medical Corporation is a medical device company based in Framingham, Massachusetts, specializing in the design, development, and marketing of minimally invasive systems for volumetric excision of tissue, particularly for diagnostic and therapeutic applications in cancer care. Founded in 1998 and originally known as Neothermia Corporation, the company has a mission to alleviate pain, restore health, and extend life. Its flagship product is a breast lesion excision system that employs vacuum-assisted, image-guided technology. This system allows for the removal of intact samples of suspicious tissue through a small incision, utilizing radio frequency energy to ensure complete excision of abnormalities. By focusing on minimally invasive procedures, Intact Medical aims to enhance patient outcomes and streamline the diagnostic process in oncology.
Sonoma Orthopedic Products
Series B in 2007
Sonoma Orthopedic Products is an orthopedic device company focused on designing, developing, and delivering proprietary orthopedic implants to address complex fractures. Utilizing the WaviBody technology platform, the company provides innovative surgical solutions that are minimally invasive, catering specifically to active patients. The firm specializes in fracture fixation devices that facilitate the repair of challenging bone geometries, enabling orthopedic surgeons to effectively restore function and return patients to their daily activities more rapidly. By prioritizing ease of use and efficacy in their products, Sonoma Orthopedic Products aims to enhance the recovery process for individuals with problematic fractures.
Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.
EKOS Corporation is a pioneering developer of ultrasound accelerated thrombolysis, specializing in the treatment of vascular thrombosis. Since its inception in 2005, the company has introduced the EkoSonic Endovascular System, which is utilized by interventional radiologists, cardiologists, and vascular surgeons at leading medical institutions globally. This innovative system facilitates faster, safer, and more complete dissolution of thrombus through controlled and selective infusion of physician-specified fluids, significantly enhancing the efficacy of thrombolytic therapies.
Asthmatx is a medical device company based in Mountain View, California, founded in 2003 and now operating as a subsidiary of Boston Scientific. The company specializes in developing and commercializing therapeutic treatments for asthma. Asthmatx has created a technology that delivers controlled thermal energy to the airways of adult patients to reduce airway smooth muscle mass through a procedure known as Bronchial Thermoplasty. Their flagship product is the Alair System, an interventional medical device designed for bronchoscopic treatment of moderate to severe asthma.
Pavad Medical
Series B in 2005
PAVAD Medical, Inc., a medical device startup company, develops therapeutic technologies in the areas of obstructive sleep apnea. The company was incorporated in 2002 and is based in Fremont, California.
OptiScan Biomedical
Venture Round in 2005
OptiScan Biomedical Corporation, founded in 1994 and located in Hayward, California, specializes in developing bedside blood monitoring systems for critically ill patients in intensive care units (ICUs). The company's flagship product, the OptiScanner 5000, is an automated glucose monitoring platform that utilizes spectroscopy technology to measure plasma glucose levels directly, eliminating the need for calibration. This system enables healthcare providers to rapidly detect changes in glucose levels, thus supporting better management of critically ill patients' health.
eNeura Therapeutics
Series B in 2005
eNeura Inc. is a medical technology company focused on developing portable, non-invasive transcranial magnetic stimulation (TMS) devices for the treatment and prevention of migraines. Its flagship product, the sTMS mini, utilizes single-pulse TMS to provide migraine relief by generating targeted magnetic fields that pass through bone and tissue. This device is designed for both acute and prophylactic treatment of migraines in adolescents aged 12 and older, as well as adults, allowing for convenient use at home or on the go. eNeura was established in 2012 and is headquartered in San Jose, California, with an additional office in Baltimore, Maryland. The company, formerly known as eNeura Therapeutics LLC, rebranded in February 2014. However, it faced financial difficulties and filed for liquidation under Chapter 7 in August 2020.
Amnis Corporation
Series C in 2005
Amnis manufactures and supplies flow cytometry products and services. Their technology is used in research and clinical studies with biomedical and therapeutic applications, including investigating the role of the body’s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients.
Alteer
Venture Round in 2005
Alteer optimizes overall performance of medical practices of any size. Alteer’s Internet based software is the only integrated platform that eliminates paper completely and automates the entire workflow in a physician’s practice - from scheduling to charting to billing and patient messaging.
Intact Medical
Series E in 2005
Intact Medical Corporation is a medical device company based in Framingham, Massachusetts, specializing in the design, development, and marketing of minimally invasive systems for volumetric excision of tissue, particularly for diagnostic and therapeutic applications in cancer care. Founded in 1998 and originally known as Neothermia Corporation, the company has a mission to alleviate pain, restore health, and extend life. Its flagship product is a breast lesion excision system that employs vacuum-assisted, image-guided technology. This system allows for the removal of intact samples of suspicious tissue through a small incision, utilizing radio frequency energy to ensure complete excision of abnormalities. By focusing on minimally invasive procedures, Intact Medical aims to enhance patient outcomes and streamline the diagnostic process in oncology.
PolyRemedy
Series A in 2005
PolyRemedy offers integrated wound management systems designed to increase consistency by extending wound care expertise to the point of care. The PolyRemedy Personalized Woundcare System (PWS) enables clinicians to document care through easy-to-use, web-based assessment tools and order personalized wound dressings, while also providing critical and unprecedented visibility into wound care data. It was founded in 2004 and is headquartered in Concord, Massachusetts.
EKOS Corporation is a pioneering developer of ultrasound accelerated thrombolysis, specializing in the treatment of vascular thrombosis. Since its inception in 2005, the company has introduced the EkoSonic Endovascular System, which is utilized by interventional radiologists, cardiologists, and vascular surgeons at leading medical institutions globally. This innovative system facilitates faster, safer, and more complete dissolution of thrombus through controlled and selective infusion of physician-specified fluids, significantly enhancing the efficacy of thrombolytic therapies.
Aesthera is a California-based company dedicated to advancing high technology aesthetics through its innovative light-based treatment systems. Founded by a team with extensive experience in laser research and development, as well as strong ties to the medical community, Aesthera is known for its pioneering Photopneumatic Therapy (PPx). This groundbreaking therapy offers a range of firsts in the aesthetic treatment field, including painless procedures, no need for pre-treatments, and the ability to treat areas such as legs and backs in under twenty minutes. The company emphasizes safety and efficacy, providing hygienic treatments that are significantly safer and highly effective for both physicians and patients.
Insulet Corporation, established in 2000, specializes in the development, manufacturing, and sale of insulin delivery systems for individuals with insulin-dependent diabetes. Its flagship product, the Omnipod System, comprises a self-adhesive, disposable, and tubeless device worn on the body for up to three days, along with a wireless, handheld personal diabetes manager. The company primarily sells its products through independent distributors, pharmacies, and directly to patients, with a presence in the United States, Canada, Europe, and the Middle East. Insulet's mission is to enhance the lives of people with diabetes by providing a user-friendly, pain-free, and automated insulin delivery solution.
Aesthera is a California-based company dedicated to advancing high technology aesthetics through its innovative light-based treatment systems. Founded by a team with extensive experience in laser research and development, as well as strong ties to the medical community, Aesthera is known for its pioneering Photopneumatic Therapy (PPx). This groundbreaking therapy offers a range of firsts in the aesthetic treatment field, including painless procedures, no need for pre-treatments, and the ability to treat areas such as legs and backs in under twenty minutes. The company emphasizes safety and efficacy, providing hygienic treatments that are significantly safer and highly effective for both physicians and patients.
Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.
Sleep Solutions
Venture Round in 2003
Sleep Solutions (SSI) is a privately held diagnostic service provider specializing in the evaluation and home testing of sleep-disordered breathing, particularly Obstructive Sleep Apnea (OSA). The company offers an efficient and cost-effective alternative to traditional in-laboratory sleep studies, utilizing its proprietary sound analysis technology. Through its NovaSom QSG home-diagnostic system, Sleep Solutions delivers testing directly to patients, facilitating a more comfortable experience. In addition to diagnosis, the company provides services focused on therapy and compliance management for individuals affected by sleep-disordered breathing.
Intact Medical
Series D in 2003
Intact Medical Corporation is a medical device company based in Framingham, Massachusetts, specializing in the design, development, and marketing of minimally invasive systems for volumetric excision of tissue, particularly for diagnostic and therapeutic applications in cancer care. Founded in 1998 and originally known as Neothermia Corporation, the company has a mission to alleviate pain, restore health, and extend life. Its flagship product is a breast lesion excision system that employs vacuum-assisted, image-guided technology. This system allows for the removal of intact samples of suspicious tissue through a small incision, utilizing radio frequency energy to ensure complete excision of abnormalities. By focusing on minimally invasive procedures, Intact Medical aims to enhance patient outcomes and streamline the diagnostic process in oncology.
eNeura Therapeutics
Series A in 2002
eNeura Inc. is a medical technology company focused on developing portable, non-invasive transcranial magnetic stimulation (TMS) devices for the treatment and prevention of migraines. Its flagship product, the sTMS mini, utilizes single-pulse TMS to provide migraine relief by generating targeted magnetic fields that pass through bone and tissue. This device is designed for both acute and prophylactic treatment of migraines in adolescents aged 12 and older, as well as adults, allowing for convenient use at home or on the go. eNeura was established in 2012 and is headquartered in San Jose, California, with an additional office in Baltimore, Maryland. The company, formerly known as eNeura Therapeutics LLC, rebranded in February 2014. However, it faced financial difficulties and filed for liquidation under Chapter 7 in August 2020.
Sleep Solutions
Series E in 2002
Sleep Solutions (SSI) is a privately held diagnostic service provider specializing in the evaluation and home testing of sleep-disordered breathing, particularly Obstructive Sleep Apnea (OSA). The company offers an efficient and cost-effective alternative to traditional in-laboratory sleep studies, utilizing its proprietary sound analysis technology. Through its NovaSom QSG home-diagnostic system, Sleep Solutions delivers testing directly to patients, facilitating a more comfortable experience. In addition to diagnosis, the company provides services focused on therapy and compliance management for individuals affected by sleep-disordered breathing.
Genteric, Inc. develops gene-based drug delivery that employs the secretor organs of the patient’s gastrointestinal system to produce and release therapeutic proteins into the bloodstream.
Sleep Solutions
Series D in 2000
Sleep Solutions (SSI) is a privately held diagnostic service provider specializing in the evaluation and home testing of sleep-disordered breathing, particularly Obstructive Sleep Apnea (OSA). The company offers an efficient and cost-effective alternative to traditional in-laboratory sleep studies, utilizing its proprietary sound analysis technology. Through its NovaSom QSG home-diagnostic system, Sleep Solutions delivers testing directly to patients, facilitating a more comfortable experience. In addition to diagnosis, the company provides services focused on therapy and compliance management for individuals affected by sleep-disordered breathing.
Genteric, Inc. develops gene-based drug delivery that employs the secretor organs of the patient’s gastrointestinal system to produce and release therapeutic proteins into the bloodstream.
Spinal Dynamics
Series A in 1997
Spinal Dynamics develops neuro-surgical devices for the replacement of spinal disks. The company's Bryan Cervical Disc System is an implanted prosthesis designed to replace and mimic the flexibility and shock-absorbing characteristics of natural intervertebral discs. It features a shock-absorbing elastomer that is intended to cushion the vertebrae and allow movement of the head and neck and is designed to replace the disc that is removed from the patient in cervical spine surgery.